Dose augmentation of tumor necrosis factor inhibitors is frequently performed in persons with inflammatory bowel disease in the absence of objective evidence of active inflammation
Journal of Clinical Gastroenterology — Elias ED, Bernstein CN, Singh H, et al. | January 08, 2021
The present study was conducted to ascertain the incidence of anti-TNF dose augmentation and the frequency with which it is preceded by the objective assessment of inflammatory bowel disease (IBD) activity. Researchers enrolled a total of 838 individuals, 70.4% of whom had Crohn’s disease, 29.6% of whom had ulcerative colitis or IBD unclassified. They noted time from anti-TNF initiation to dose augmentation for all previously biologic-naïve patients. The data demonstrated that one-third of previously biologic-naïve patients had anti-TNF doses increased within the first 12 months of treatment. It was shown that dose augmentation frequently occurred without objective evidence of inflammatory disease activity.
At 12 months, the cumulative incidence of dose augmentation was 32.9%. Compared to Crohn’s disease, dose augmentation was seen more often in ulcerative colitis.